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Abstract Expression of the transcription factor hypoxia-
inducible factor 1 (HIF-1), which plays a key role in
cellular adaptation to hypoxia, was investigated in normal
colorectal mucosa (ten), adenomas (61), and carcinomas
(23). Tissue samples were analyzed for HIF-1α, its
upstream regulators, von Hippel–Lindau factor, AKT, and
mammalian target of rapamycin (mTOR) and its down-
stream targets glucose transporter 1 (GLUT1), carbonic
anhydrase IX, stromal-cell-derived factor 1 (SDF-1) by
immunohistochemistry. In normal colorectal mucosa, HIF-
1α was observed in almost all nuclei of surface epithelial
cells, probably secondary to a gradient of oxygenation, as
indicated by pimonidazole staining. The same staining
pattern was present in 87% of adenomas. In carcinomas,
HIF-1α was present predominantly around areas of necrosis
(78%). Active AKT and mTOR, were present in all
adenomas, carcinomas, and in normal colorectal mucosa.
GLUT1 and SDF-1 were present in the normal surface
epithelium of all adenoma cases, whereas in the carcinoma
GLUT1 was located around necrotic regions and SDF-1
was present in all epithelial cells. In conclusion, HIF-1α
appears to be physiologically expressed in the upper part of
the colorectal mucosa. The present observations support
that upregulation of HIF-1α and its downstream targets
GLUT1 and SDF-1 in colorectal adenomas and carcinomas




Colorectal carcinomas arise from normal epithelial cells of
the colorectal mucosa through an adenoma stage. The
transition from benign adenomas to malignant carcinomas,
occurring in about 5% of all adenomas, is only beginning to
be explored in appreciable detail. Biological changes
involved in this process include important signaling path-
ways like the mammalian target of rapamycin (mTOR)–
AKT pathway while recently also a role for hypoxia-driven
signaling was shown [6, 14]. Both pathways are mediated
by the transcription factor hypoxia-inducible factor 1 (HIF-
1) as depicted in Fig. 1. HIF-1 is involved in cellular
adaptation to hypoxia in solid tumors, including stimulation
of angiogenesis and glycolysis [33]. HIF-1 consists of two
subunits of which the β-subunit is constitutively expressed,
whereas HIF-1α is regulated in particular by the oxygen
level. Under normoxia, the HIF-1α protein is hydroxylated
by prolyl hydroxylases [15, 16], which enables the von
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Utrecht, The NetherlandsHippel–Lindau factor (VHL) to bind, resulting in ubiqui-
nation and rapid degradation by the proteosome [27]. HIF-
1α is overexpressed in many solid tumors [38] and its
presence has been correlated with, i.e., poor prognosis in
breast and colorectal cancer patients [4, 36]. Stromal
expression of hypoxia-regulated proteins is an adverse
prognostic factor in colorectal carcinomas.
High protein levels of HIF-1α are not only caused by
hypoxia but can also be induced by the absence of wild-
type protein 53, mutated VHL and other tumor suppressor
genes, as well as by activation of oncogenes like Her2neu
(c-erbB-2) [24]. In addition, growth factors play a role.
However, both hypoxia and signaling-mediated HIF-1
stimulation are mediated by the phosphatidylinositol 3-
kinase (PI3K)–AKT, and the mTOR pathway [8]. Interest-
ingly, both the serine–threonine protein kinase AKT as well
as mTOR have been suggested to play a role in an early
stage of colorectal carcinogenesis [2, 30]. Furthermore, the
presence of a non-hypoxic HIF-1 induction has also been
suggested, in colorectal adenomas [9].
Upon HIF-1 activation, multiple target genes become
transcriptionally active, including genes involved in anaer-
obic glycolysis, metabolism, and angiogenesis. This
includes glucose transporter 1 (GLUT1), which facilitates
cellular glucose uptake [11, 26] and the angiogenesis-
associated genes vascular endothelial growth factor and
stromal-cell-derivedfactor1 (SDF-1)alsoknownasCXCL12
[5]. Furthermore, carbonic anhydrase IX (CA IX) which is
prominently induced by hypoxia and is therefore considered
to be an intrinsic hypoxia marker, which correlates with a
chemical marker of hypoxia, pimonidazole [1, 17, 23, 28].
An additional function of CA IX is in the regulation of the
maintenance of the physiological equilibrium in normal
gastrointestinal tissue [31].
The present study aims to analyze the role HIF-1 in
normal colorectal mucosa, adenomas, and carcinomas. To
this end, the presence of HIF-1α as well as of its
downstream targets GLUT1, SDF-1, and CA IX were
analyzed in normal colon tissue, colorectal adenomas, and
carcinomas. To explore the possible cause of HIF-1 over-
expression, i.e., hypoxia or oncogenic stimulation, both the
presence of the chemical hypoxia marker pimonidazole and




A total of 84 tissue samples were studied, consisting of 61
colorectal adenomas, 20 of which contained already a focus
of carcinoma and are therefore referred to as progressed
adenomas, in contrast to the 41 adenomas with dysplasia
only, which are referred to as nonprogressed adenomas. In
addition, 23 colorectal carcinomas were analyzed. These
samples were obtained from 75 patients, 37 of which were
female and 38 male. Mean age was 67.8 years (range 40–
89). Normal mucosa samples were obtained from the
resection margins of colectomy specimens from ten patients
with colorectal cancer. The study was approved by the
Institutional Review Board and was in accordance with
Dutch medical ethical guidelines.
Determination of hypoxic regions
Hypoxic regions in mouse tissues were visualized using the
Hydroxyprobe-1 kit (Chemicon International, Temecula,
CA, USA). These experiments were approved by the
animal experimentation ethics committee, according to
local and governmental regulations.
Briefly, mice were injected intravenously with pimonida-
zole (60-mg/kg body weight), which forms adducts from
reductively activated pimonidazole in hypoxic cells. Mice
were killed 90 min later by asphyxiation in CO2.T h e
Hydroxyprobe-1 monoclonal antibody was biotinylated
using D-biotinyl-ɛ-aminocaproic acid N-hydroxysuccinimide
ester (Boehringer Mannheim) and was used to stain
Fig. 1 Schematic representation of the interaction of the analyzed
proteins. The PI3K–AKT–mTOR pathway is inducing HIF-1α.I n
addition, the absence of hypoxia prevents HIF-1α from degradation
mediated by VHL. When HIF-1α is present, it binds to HIF-1 β in the
nucleus. The formed complex activates target genes, like GLUT1,
SDF1, and CA IX
536 Virchows Arch (2008) 452:535–544pimonidazole adducts in formalin-fixed paraffin-embedded
tissues according to recommendations by the manufacturer.
Immunohistochemistry
Immunohistochemistry was performed on 4-μm-thick full-
block consecutive sections. Slides were deparaffinized,
followed by rehydration, and subsequently staining in
batches with the antibodies described in Tables 1 and 2.
HIF-1α staining was performed as described previously [3].
In brief, antigen retrieval was performed in antigen retrieval
solution (DAKO, Glostrup, Denmark) for 45 min at 96°C.
The primary antibody against HIF-1α was incubated at a
dilution of 1:500 for 30 min at room temperature and the
catalyzed signal amplification system (DAKO) was used
for detecting HIF-1α staining.
For CA IX staining, no antigen retrieval step was used.
Slides were incubated with a mouse primary antibody to
CA IX in a 1:50 dilution for 30 min at room temperature.
Detection was performed with the Envision+ system–
horseradish peroxidase system for mouse primary anti-
bodies (DAKO).
GLUT-1 staining was performed with a rabbit polyclonal
anti-GLUT1 (antibody clone A 3536, DAKO, dilution 1:400)
without antigen retrieval and subsequently developed with a
standard avidin–biotinylated peroxidase complex (DAKO).
Staining procedures for AKT and mTOR were identical.
After antigen retrieval, endogenous peroxidase activity was
blocked for 10 min in methanol containing 0.3% hydrogen
peroxide. The AKT antibody (Phospho-Akt (Ser473)) and
mTOR antibody (Phospho-mTOR (Ser2448)) both obtained
from Cell Signaling (Danvers, MA, USA) were incubated
overnight at 4°C in a 1:50 dilution and subsequently
detected with a standard avidin–biotinylated peroxidase
complex.
SDF-1 staining was performed similar to the AKT and
mTOR staining, except for the secondary antibody, which
was a goat anti-rabbit antibody in this case.
For VHL staining, antigen retrieval was performed and
endogenous peroxidase was blocked as the AKT and
mTOR staining. Primary antibody against VHL was
incubated for 60 min by room temperature, followed by
Powervision (Immunologic, Duiven, the Netherlands) incu-
bation for 30 min and subsequently the staining was
detected with diaminobenzidine (SIGMA FAST™ 3,3′-
diaminobenzidine tablets, Sigma Aldrich, St. Louis, MO,
USA).
Before the slides were mounted with cover slips, all
sections were counterstained for 30 s with Mayer’s
hematoxylin and dehydrated in 70%, 96%, and subsequent-
ly 100% ethanol and finally in xylene.
Evaluation and statistics
The intensity of the staining was compared between the
normal mucosa, nonprogressed, progressed adenomas, and
carcinomas and scored by two investigators. Staining
intensity was scored in four classes (0 to 3) taking the
negative control as a reference for score 0 and the positive
control (clear cell renal adenocarcinomas (Grawitz tumor)
as a reference for score 3). For HIF-1α, only nuclear
staining was scored, for CA IX, membrane staining, and
AKT and SDF-1 cytoplasmic staining, for mTOR predom-
inantly cytoplasmic but also membrane staining was scored.
Significance of differences between categories was ana-
lyzed by means of the Kruskal Wallis test. P-values<0.05
were considered to be significant.
Results
HIF-1α expression and its regulators hypoxia and VHL
In normal colorectal mucosa nine out of ten samples
showed HIF-1α present in nuclei of the surface epithelium
(Fig. 2). To evaluate whether hypoxia played a physiologic
Table 1 Details of the immunohistochemical stainings
Antibody Species Company and institutes Dilution Incubation Antigen retrieval Detection
HIF-1α Mouse BD Pharmingen 1/500 30′ RT WB TRS 97°C 45′ CSA
Akt Rabbit Cell Signaling 1/50 o/n 4°C WB Citr 97°C 10′ ABC
mTOR Rabbit Cell Signaling 1/50 o/n 4°C WB Citr 97°C 10′ ABC
VHL Mouse BD Pharmingen 1/100 60′ RT WB Citr 97°C 20′ Powervision
CA IX Mouse Lab Harris 1/50 30′ RT none Envision+
Glut-1 Rabbit DAKO 1/400 60′ RT WB Citr 97°C 20′ ABC
SDF-1 Mouse R&D systems 1/400 o/n 4°C WB Citr 97°C 10′ ABC
Hydroxyprobe-1 Mouse Chemicon International 1/200 40′RT 0.01% pronase in PBS 40°C for 40′ ABC
BD Transduction laboratories, Mab monoclonal antibody, PAb polyclonal antibody, RT room temperature, WB water bath, TRS target retrieval
solution (DAKO), Citr citrate buffer 10 mM pH 6.0, CSA catalyzed signal amplification system (DAKO), ABC avidin–biotinylated peroxidase
complex, Powervision from immunologic R&D systems
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mucosa, we used mice that were injected with pimonida-
zole, a chemical marker of hypoxia that can be visualized
by immunohistochemistry. The presence of tissue hypoxia
was demonstrated in the surface epithelium of normal colon
mucosa of the treated mice (Fig. 3). The pattern of hypoxic
cells in the normal colorectal mucosa in mice matched with
the distribution of HIF-1α immunohistochemical staining
in human colorectal mucosa.
The presence of HIF-1α in normal colorectal mucosa
was compared with that in adenomas and carcinomas.
Adenomas displayed HIF-1α expression in 53 of the 61
cases, predominantly at the surface, gradually decreasing
towards the center of the adenomas. No differences were
seen between nonprogressed and progressed adenomas
(85% and 90%, respectively), as shown in Table 2. Of the
carcinomas, 78% (n=18) were positive, showing nuclear
staining of HIF-1α in epithelial tumor cells. In carcinomas,
a decreasing gradient of HIF-1α staining was observed
from necrotic areas towards the well-vascularized stroma.
Besides the epithelial tumor cells, in carcinomas, inflam-
matory cells in the tumor-associated stroma, and in five
cases B-cells in lymph follicles, were positive for HIF-1α.
Statistical analysis showed no significant differences in
intensity of HIF-1α staining between normal mucosa,
adenomas, and carcinomas.
VHL, the regulator of HIF-1α degradation, was also
analyzed by means of immunohistochemistry (Fig. 2). VHL
expression was observed in all epithelial cells in normal
colorectal mucosa as well as in colorectal adenomas and
carcinomas.
AKT and mTOR, oncogenic pathways regulating HIF-1α
To investigate whether, in addition to hypoxia, oncogenes
and/or growth factors can contribute to the elevated HIF-
1α, we studied the presence of phosphorylated forms of
AKT and mTOR, which reflect an active state of the
oncogene-driven pathway of HIF-1α activation. Low-
intensity cytoplasmic staining for the active form of AKT
(P-AKT) was seen in epithelial cells of normal mucosa in
all tissues (Fig. 4). Positive staining was also seen in the
smooth muscle cells of the muscularis propria and
muscularis mucosae and in the walls of blood vessels. In
Table 2 Number (and
percentages) of HIF-1α,
P-AKT, P-mTOR, VHL, CA
IX, GLUT1, and SDF-1 ex-
pression in nonprogressed and
progressed colorectal adeno-
mas and adenocarcinomas in
the respective categories of
staining intensity









HIF-1 Neg 6 (15) 2 (10) 5 (22) 0.8
+ 0 (0) 2 (10) 1 (4)
++ 7 (17) 3 (15) 3 (13)
+++ 28 (68) 13 (65) 14 (61)
AKT Neg 0 (0) 0 (0) 0 (0) 0.1
+ 12 (29) 7 (35) 0 (0)
++ 11 (27) 5 (25) 10 (43)
+++ 18 (78) 8 (40) 13 (57)
mTOR Neg 2 (5) 0 (0)
a 0 (0) 0.4
+ 2 (5) 3 (16) 0 (0)
++ 12 (29) 6 (32) 7 (30)
+++ 25 (61) 10 (53) 16 (70)
VHL Neg 0 (0)
a 1 (5) 0 (0) 0.9
+ 7 (18) 0 (0) 1 (4)
++ 12 (30) 11 (55) 11 (48)
+++ 21 (53) 8 (40) 11 (48)
CA IX Neg 10 (24) 4 (20) 1 (4) 0.3
+ 0 (0) 0 (0) 0 (0)
++ 1 (2) 2 (10) 2 (9)
+++ 30 (73) 14 (70) 20 (87)
GLUT1 Neg 0 (0) 1 (5) 0 (0) 0.02
+ 8 (20) 6 (30) 0 (0)
++ 15 (37) 4 (20) 6 (26)
+++ 18 (44) 9 (45) 17 (74)
SDF1 Neg 8 (20)
a 7 (37)
a 0 (0) <0.005
+ 4 (10) 4 (21) 0 (0)
++ 13 (33) 2 (11) 5 (22)
+++ 15 (38) 6 (32) 18 (78)
538 Virchows Arch (2008) 452:535–544adenomas, staining in epithelial cells was more intense,
present throughout the neoplastic tissue, and observed in all
cases. Staining patterns in adenocarcinomas were similar
and also observed in all samples analyzed.
Active mTOR was only present as a cytoplasmatic
staining; nuclear staining was not observed in any of the
cases (Fig. 4). In normal mucosa, mTOR was detected in
the surface epithelium in all tissues. Likewise, in adenoma
samples, mTOR was expressed in the surface epithelium
but also more diffusely throughout the adenomas. In
adenocarcinomas, staining patterns were diffused across
the whole tumor, but more intense expression was detected
in areas surrounding necrosis. Higher levels of active
mTOR were observed at the invasive front of the tumor.
In the adenocarcinomas, besides the cytoplasmic staining in
some cells, a clear cellular membrane staining was
observed. In all normal mucosa samples, adenomas, and
carcinomas, mTOR was present, except for 5% of the
nonprogressed adenomas, which were negative for mTOR
(Table 2).
Expression of the HIF1 downstream targets Glut1
and SDF-1
To investigate to what extent downstream pathways were
affected by HIF-1 upregulation, several HIF-1 target genes,
Fig. 3 Detection of hypoxia in
murine colorectal mucosa by
pimonidazole. a Colorectal mu-
cosa of a non-injected mouse,
b colorectal mucosa of a mouse
that was injected intravenously
with pimonidazole. After
90 min, the mouse was killed
and colon tissue harvested and
formalin fixed. Immunohisto-
chemical staining against pimo-
nidazole revealed hypoxia in the
surface epithelium of the normal
colon mucosa
Fig. 2 Serial sections of normal
colon mucosa, colorectal adeno-
ma, and adenocarcinoma ana-
lyzed for HIF-1α and VHL
expression. HIF-1α staining was
observed in the nuclei of surface
epithelium of normal mucosa
and colorectal adenoma, where-
as in adenocarcinomas HIF-1α
was present near hypoxic
regions with necrosis. VHL ex-
pression was observed in the
cytoplasma of all epithelial cells
of normal mucosa, adenomas,
and adenocarcinomas
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mucosa, adenomas, and adenocarcinomas. Expression of
GLUT1, which is involved in glucose metabolism, was
closely correlated with HIF-1α in all colon tissues
analyzed. In normal colon mucosa, GLUT1 expression
showed a gradient from the surface epithelium towards the
basis of the crypts (Fig. 5). All normal tissues showed a
positive GLUT1 staining. In nonprogressed adenomas, all
cases showed GLUT1 expression compared to 95% of
progressed adenomas. All adenocarcinomas (n=23) were
positive for GLUT1 as well. Staining was localized at the
cell membrane of epithelial cells in normal mucosa,
adenomas, and adenocarcinomas (Fig. 5). Most intense
staining was seen at the surface epithelium of adenomas
and in the vicinity of necrosis in carcinomas. As to staining
intensity, a significant difference was detected between the
adenomas and the carcinomas (Table 2).
In normal colon tissue, SDF-1 expression was compa-
rable to that of HIF-1α, i.e., it was detected in a gradient
from the surface epithelium towards the basis of the
crypts. However, in all colorectal adenomas and adeno-
carcinomas, intense SDF-1 expression was observed in the
epithelial cells, which was located in the cell membrane
and cytoplasm (Fig. 5). Because this epithelial SDF-1
expression was seen in all epithelial cells, it co-localized
only partly with HIF-1α presence. In contrast to the
comparable intensity of the HIF-1α staining in adenomas
and adenocarcinomas, the SDF-1 staining intensity was
much higher in adenocarcinomas than in the adenomas
(Table 2). In addition to the epithelial expression of SDF-1,
endothelial cells of blood vessels stained positive for SDF-1
(Fig. 6).
Expression of CA IX
CA IX was originally identified in gastrointestinal tissues
and later recognized as a HIF-1 target gene in many
tissues. In normal mucosa, the presence of CA IX
actually did not co-localize with that of HIF-1α.C AI X
was observed in the bottom parts of the crypts, i.e., in
the proliferative compartment, in contrast to HIF-1α,
which was present in the surface epithelium. Seventy
percent of the normal tissues showed CA IX expression.
In adenomas and particular adenocarcinomas, CA IX and
HIF-1 expressions had more resemblance. In adenomas,
CA IX was present in a more diffuse pattern throughout
the whole adenoma, including the surface epithelium
(Fig. 5). In the adenocarcinomas, CA IX showed a peri-
necrotic staining, mainly co-localizing with the HIF-1α
expression.
Fig. 4 Typical immunohisto-
chemical staining patterns of
the active forms of AKT (P-
AKT) and mTOR (P-mTOR)i n
normal colon mucosa, colorectal
adenoma, and adenocarcinomas.
Presence of active AKT is seen
in the cytoplasm of all epithelial
cells with increasing intensities
from the normal mucosa to-
wards adenocarcinoma. Pres-
ence of active mTOR is
restricted to the surface epithe-
lium in normal mucosa and
adenomas. In adenocarcinomas,
cells surrounding necrotic areas
show active mTOR as well. In
addition, in adenocarcinomas,
intracellular localization of
mTOR changes from cytoplasm
towards cellular membrane
staining
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The present study demonstrates the presence of nuclear
HIF-1α in the surface epithelium of normal colon and
adenomas and in areas associated with peri-necrotic areas
of colon adenocarcinoma. The data support a hypoxia-
induced HIF-1 cascade, both in normal and neoplastic
colorectal mucosa, as suggested by pimonidazole and HIF-
1α patterns in association with GLUT1 and SDF-1 in
normal colorectal mucosa and adenomas, as well as peri-
necrotic HIF-1α and CA IX patterns in colorectal carcino-
mas. The occurrence of hypoxia around the surface
epithelium was confirmed by pimonidazole staining of
unaffected murine colon. Furthermore, hypoxia and the
oncogenic activation of the AKT–mTOR pathway both
contributed to HIF-1 expression in adenomas and adeno-
carcinomas. Moreover, the expression patterns of CA IX in
normal mucosa and SDF-1 in neoplastic mucosa pointed to
additional regulations independent from HIF-1.
The hypoxia–HIF-1 cascade
The presence of HIF-1α under physiological circumstances
in the surface epithelium of normal colorectal mucosa
observed in the present study may be due to the anaerobic
environment in the lumen of the colon, which contributes to
a relatively hypoxic state of especially this surface
epithelium. Indeed, we observed accumulation of the
chemical hypoxia marker pimonidazole particularly in the
Fig. 6 SDF-1 expression in epithelial and endothelial cells of normal
detected by immunohistochemistry
Fig. 5 Typical immunohisto-
chemical staining patterns of
HIF-1α, GLUT1, SDF-1, and
CA IX in normal colon mucosa,
colorectal adenomas, and
adenocarcinomas. The down-
stream targets of HIF-1, i.e.,
SDF-1, GLUT1, and CA IX,
have predominantly overlapping
staining with the presence of
HIF-1. However, in normal mu-
cosa, CA IX is not expressed in
the HIF-1α positive surface ep-
ithelium but is expressed in the
basal of the crypts. In adenocar-
cinomas, SDF-1 is not only
present in HIF-1α-positive cells
but in all epithelial cells
Virchows Arch (2008) 452:535–544 541surface epithelium, indicating low oxygen levels [19]. The
presence of pimonidazole showed a gradient towards the
basis of the crypts, suggesting that the cause of hypoxia
was indeed related to the anaerobic lumen. Apparently, the
capillaries in the surface regions of the colon epithelium
were unable to cope with the high oxygen demand of the
tissue. This strongly suggests that these hypoxic areas may
induce HIF-1α, which contributes to a sustained pressure
on the stimulation of angiogenesis and glycolysis to adjust
the energy levels of these cells.
Although immunohistochemical analysis of patient sam-
ples does not allow a formal analysis of functional
relationships, it is highly likely that the HIF-1 detected in
normal colorectal mucosa was transcriptionally active
because HIF-1α was detected in the nuclei and the HIF-1
downstream targets GLUT1 and SDF-1 were present in the
same regions where HIF-1α was found.
In 87% of colorectal adenomas, HIF-1α was present,
showing staining predominantly in the nuclei of the surface
epithelium. In colorectal adenocarcinomas, the presence of
HIF-1α changes from the surface epithelium to epithelium
cells surrounding regions of necrosis, indicating severe
hypoxia. Presence of HIF-1α in the nuclei of epithelial cells
went along with expression of the downstream targets
GLUT1 and SDF1 in all different stages of the colon
carcinogenesis.
In contrast to SDF-1 and GLUT1, the downstream target
CA IX, known as a stringent hypoxia marker [35], did not
co-localize with HIF-1α staining in normal colorectal
mucosa. It should be noted that CA IX was originally
described to have a role in maintaining the physiological
equilibrium in the gastrointestinal tract. In fact, CA IX was
more abundant in the basal half of the crypts, containing the
proliferating compartment, rather than in the upper half of
t h em u c o s aw h e r eH I F - 1 α expression was observed.
Indeed, co-localization of CA IX with Ki-67, a proliferation
marker, has been found in colorectal cancer [31]. The lack
of HIF-1α in the CA IX-positive regions indicates an HIF-
1α-independent regulation of CA IX in normal colon
epithelium. CA IX expression was reported to be also
regulated by the transcription factor SP1 [18, 31].
Oncogenic upregulation of HIF-1
Oncogene-dependent regulation of HIF-1 can be mediated
by the AKT–mTOR pathway [24, 39]. In the present study,
in epithelium of all normal colorectal mucosa, a weak
staining of P-AKT was observed, confirming data of Itoh et
al. [14]. In all adenomas and adenocarcinomas analyzed,
the active (phosphorylated) forms of AKT and mTOR were
detected as well. Especially active mTOR showed co-
localization with HIF-1α in normal tissue as well as in
adenomas and adenocarcinomas. Co-localization of P-AKT
with HIF-1α was less evident. Recently, in breast cancer, it
has been shown that in the absence of P-AKT, only low
levels of HIF-1α could be detected while in the presence of
P-AKT high HIF-1α protein levels were observed [10]. In
colorectal tumorigenesis, this regulation mechanism may be
less relevant because staining was already observed in
normal tissue. In addition, the presence of active AKT was
not HIF-1 related because in adenocarcinomas P-AKT was
present in a higher percentage of cells present than HIF-1α.
The downstream target of AKT, mTOR, displayed compa-
rable cellular expression patterns to HIF-1α in normal,
adenomas, and carcinomas. This suggests that the AKT–
mTOR–HIF-1α axis may be important in tumor growth and
development as was seen in prostate epithelial cells [25].
Expression of VHL
An alternative mechanism that can lead to HIF-1α over-
expression is loss of VHL expression. In normal colon
mucosa, VHL is expressed, while in colorectal tumors VHL
has been found to be lost or mutated in 11% of cases [7,
21]. Mutations in the VHL gene have been reported to
result in cytoplasmic staining of HIF-1α in colorectal
cancer in one study [22], while this could not be confirmed
in another study of 80 patients [40]. Also in the present
study, no cytoplasmic staining of HIF-1 α was seen at all,
and VHL expression was seen in all epithelial cells of
normal mucosa, colorectal adenomas, and carcinoma.
Expression of SDF1
SDF-1 was investigated in the present study as a down-
stream target of HIF-1 [13, 32]. Surprisingly, epithelial cells
showed much stronger SDF-1 expression than endothelial
cells lining blood vessels. In addition, expression was not
merely restricted to areas showing HIF-1α staining but was
observed in all epithelial adenomas and adenocarcinomas.
SDF-1 staining in tumors cells has also been reported in
breast cancer patients [29] and in clear cell–renal cell
carcinomas, in which HIF-1α is constitutively expressed
[37]. The intense staining of the colon tumor cells suggests
that SDF-1 not only has a function in attracting circulating
progenitor cells towards the angiogenic areas [12]. Indeed,
SDF-1 stimulates intestinal epithelial cell migration and
enhances the integrity of the mucosal barrier [34].
The level of expression of SDF-1 might also play a role
in tumorigenesis because it is related with prognosis in
colorectal cancer. The presence of its coding mRNA and
the mRNA of its receptor, CXCR4, have been shown to be
a poor prognostic factor [20]. In tumor formation, SDF-1
may bear impact on the recruitment of various types of
progenitor cells needed for enhanced growth of the tumor
tissue [29]. Our study supports a role of SDF-1 in
542 Virchows Arch (2008) 452:535–544carcinogenesis because SDF-1 staining becomes more
intense with the progression of normal colon tissue toward
carcinomas. However, future studies are needed to substan-
tiate such role.
Conclusion
T h ec o m m o ne x p r e s s i o no fH I F - 1 αin the surface epithelium of
thecolorectalmucosasuggeststhatHIF-1mayplayaroleinthe
physiology of normal colon tissue. HIF-1α presence does not
appear to be related to progression of colorectal carcinogenesis
in contrast to GLUT1 and SDF-1, which are expressed more
intensely at later stages of this process.
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